Cerus Corporation 2017 Form 10-K Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System, a pathogen-reduction technology for transfusion platelets, plasma and red blood cells. The filing covers the fiscal year ended December 31, 2017; fourth-quarter figures are unaudited. Platelet and plasma systems were commercialized in the U.S. and selected international markets, while the red blood cell system remained investigational.
As of December 31, 2017, Cerus had 215 employees and operated as one blood-safety segment. Product sales were concentrated geographically and by customer; Etablissement Français du Sang represented 22% of 2017 product revenue.
Financial performance and key metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Product revenue | $43.6 million | $37.2 million | 17% increase |
| Government contract revenue | $7.8 million | $2.1 million | 271% increase |
| Total revenue | $51.3 million | $39.3 million | 31% increase |
| Gross profit on product revenue | $21.0 million | $16.9 million | 24.6% increase |
| Product gross margin | 48% | 45% | 300 basis-point increase |
| Operating loss | $(57.5) million | $(61.4) million | Improved by $3.9 million |
| Net loss | $(60.6) million | $(62.9) million | Improved by $2.3 million |
| Basic net loss per share | $(0.56) | $(0.62) | Improved |
| Research and development expense | $33.7 million | $31.3 million | 8% increase |
| Sales, general and administrative expense | $52.4 million | $48.8 million | 8% increase |
Product revenue growth primarily reflected higher platelet-system disposable-kit demand in Europe, including the initial French national rollout, increased routine use by U.S. customers and favorable Euro exchange rates. Plasma-kit revenue declined partially offsetting platelet growth.
Fourth-quarter 2017 product revenue was $16.2 million, compared with $10.1 million in fourth-quarter 2016. Fourth-quarter government contract revenue was $2.4 million, and quarterly net loss was $11.5 million, or $0.10 per basic and diluted share.
Cash flow, liquidity and debt
| Metric | December 31, 2017 | December 31, 2016 |
|---|---|---|
| Cash, cash equivalents and restricted cash | $13.9 million | $22.7 million |
| Short-term investments and marketable equity securities | $47.0 million | $49.1 million |
| Working capital | $66.8 million | $67.2 million |
| Total assets | $98.2 million | $103.5 million |
| Debt carrying value | $29.8 million | $19.4 million |
| Stockholders’ equity | $38.9 million | $57.8 million |
- Net cash used in operating activities was $52.2 million, compared with $53.5 million in 2016.
- Net cash provided by investing activities was $0.4 million, compared with $19.9 million used in 2016.
- Net cash provided by financing activities was $43.0 million, including $30.0 million of new term-loan proceeds and $30.2 million of net public-offering proceeds, partially offset by debt repayment.
- The Oxford credit agreement permits up to $40.0 million of secured term loans. Cerus had drawn $30.0 million at year-end, bearing approximately 8.4% interest, with the remaining $10.0 million subject to a revenue milestone.
- Contractual obligations totaled $69.9 million, including $39.8 million of debt principal and interest, $19.5 million of minimum purchase commitments, $6.6 million of manufacturing and development obligations and $3.2 million of operating leases.
Management stated that available cash, investments, expected product sales and BARDA receipts were expected to fund requirements for at least the next twelve months, but cautioned that this assessment depends on assumptions regarding revenue, BARDA funding and access to capital.
Material changes versus the prior comparable period
- Total revenue increased 31%, driven by product growth and higher BARDA reimbursement revenue.
- Product gross margin improved to 48% from 45%, primarily due to platelet-kit mix, favorable foreign exchange and operating efficiencies.
- Operating and net losses remained substantial, although both improved modestly.
- Research and development spending increased for red blood cell clinical development, platelet and plasma label-expansion work and BARDA activities.
- Debt increased following the July 2017 refinancing and draw of the $30.0 million Oxford term loan.
- Cash and restricted cash declined by $8.8 million, despite equity and debt financing, because operating activities consumed $52.2 million.
- Cerus sold its remaining Aduro Biotech shares and recognized approximately $3.5 million of gain, contributing to $3.9 million of income-tax expense.
- Common shares outstanding increased to 115.6 million at year-end from 103.5 million, reflecting equity issuance and equity compensation.
Guidance, outlook, commentary and risks
- Management expected product revenue to increase as adoption expands in the U.S., France and other accessible markets, but provided no formal numerical revenue or profitability guidance.
- The company expected continued losses and additional research, clinical, regulatory, manufacturing and commercialization spending; profitability depends on widespread market adoption.
- The red blood cell program met primary efficacy and safety endpoints in European Phase 3 acute- and chronic-anemia trials. Cerus planned a CE-mark submission in the second half of 2018, but did not expect regulatory approval within the next twelve months and had not commercialized the product anywhere.
- U.S. red blood cell development required completion of the ReDeS and ReCePI studies, additional in-vitro work and a further Phase 3 chronic-anemia trial. ReDeS enrollment was affected by 2017 hurricanes in Puerto Rico.
- The BARDA agreement could provide up to $186.2 million over five years, but only approximately $88.2 million had been committed through the base period and exercised options. Additional funding depended on BARDA exercising options and Cerus meeting milestones; BARDA could terminate for convenience.
- U.S. adoption remained dependent on blood-center process validation, site-specific licenses, hospital administrative integration, reimbursement and approval of additional product configurations.
- Cerus relies on Fresenius and other sole or limited-source suppliers. Obsolete plastics, component shortages, manufacturing nonconformities and the need to qualify alternatives could constrain supply and increase costs.
- Reported risks include clinical or regulatory failure, adverse safety findings, product recalls, customer concentration, distributor performance, foreign-exchange exposure, competition, intellectual-property disputes, healthcare-reimbursement changes and the need for additional financing.
- In January 2018, after year-end, Cerus issued 14.03 million shares at $4.10 per share for gross proceeds of approximately $57.5 million before offering expenses.
Most important facts for investors to verify
- Whether U.S. and French customer adoption converts into sustained disposable-kit volume and recurring product revenue.
- Actual cash runway after considering the $52.2 million 2017 operating cash burn, debt service, purchase commitments and planned clinical spending.
- Availability and timing of the remaining BARDA funding, milestone performance and any government audit or contract modification.
- Progress, enrollment and results of ReDeS, ReCePI and the additional U.S. red blood cell clinical requirements.
- Timing and outcome of the planned European red blood cell CE-mark submission and related manufacturing-validation activities.
- Regulatory approval of alternate plastics, redesigned illuminators and additional platelet and plasma configurations.
- Supply continuity under the Fresenius, Porex, Purolite, Nova and Ash Stevens arrangements, including minimum purchase obligations.
- Debt covenants, the revenue milestone for the undrawn $10.0 million Oxford tranche and the effect of future equity issuance on dilution.
- Customer and receivable concentration, including the three customers representing approximately 53% of year-end trade receivables.
- Whether ongoing losses, regulatory delays or weaker-than-expected adoption require additional capital beyond the January 2018 equity offering.